Peptides Agora Discloses Approximately $12,000 PEPS Treasury Acquisition

Disclosure at a glance

Peptides Agora has acquired approximately $12,000 worth of $PEPS, the token associated with PeptideSwap. This is a treasury position held by the organization. It is not an endorsement of buying, selling, or holding $PEPS, and it is not investment advice.

Digital assets are volatile. The position may lose some or all of its value. Peptides Agora may sell, reduce, or otherwise change the position in the future. If a material change occurs, we will update this disclosure.

Why we made the acquisition

Peptides Agora covers the peptide ecosystem from a research, safety, regulatory, and market-structure perspective. PeptideSwap is building a consumer-facing project around a peptide marketplace, product and seller comparison, and a learning-oriented PEPS Lab. Its public materials describe a marketplace still in development, an open $PEPS presale, and a proposed 500 million token supply with allocations for public sale, research and stewardship, product treasury, liquidity, ecosystem adoption, and strategic partners.[^1]

We made the acquisition because the project sits close to questions we expect to matter in the broader peptide ecosystem: how people discover product information, how sellers present offers and terms, how consumer education is delivered, and how digital communities form around a fast-moving category. We consider that a relevant area to observe as the marketplace develops.

The acquisition does not mean that Peptides Agora has verified the project, its future roadmap, its technology, its token economics, its team, or any outcome described in its materials. It is a limited financial position, not a guarantee of a commercial relationship, product integration, listing, partnership, or editorial endorsement.

What the position does and does not represent

The approximately $12,000 figure refers to the value of the acquisition at the time it was made. It should not be read as a price target, a valuation statement, a liquidity claim, or a recommendation to others. We are not publishing a token quantity because token balances, execution prices, and liquidity conditions can change and may be misunderstood without full transaction context.

We are also not presenting a chain, contract address, or wallet address here. Readers who choose to research $PEPS should rely on links published through PeptideSwap's official channels and independently verify any asset before interacting with a wallet, presale, or marketplace. Impersonation, fraudulent links, and unverified token contracts are common digital-asset risks.

Editorial independence and conflict safeguards

This financial interest creates a conflict that readers deserve to understand. Articles, guides, tools, and other editorial material mentioning PeptideSwap or $PEPS will carry a disclosure when the relationship is materially relevant.

The holding does not change our standards for claims about peptide safety, clinical evidence, regulation, product quality, or consumer protection. We will not treat a token position as evidence that a peptide product, seller, marketplace listing, or educational claim is safe, medically appropriate, legal, or effective. Peptides Agora does not provide medical advice, and this announcement does not evaluate any peptide for human use.

Editorial coverage must continue to distinguish between a project's stated plans and independently verifiable facts. Where a claim cannot be verified from primary documentation, we will say so. Where a project is pre-launch or its roadmap may change, we will make that uncertainty clear.

Risks we considered

The risks are substantial. Digital-asset markets can move sharply, presale participation carries execution and custody risks, and early-stage product roadmaps can change or fail to ship. A token's value can be affected by market conditions, supply releases, liquidity, security incidents, regulatory action, community sentiment, and factors unrelated to the underlying product.

There are also category-specific risks. The peptide market includes regulated medicines, investigational compounds, research-use-only materials, and products that should not be represented as approved therapies. Any platform operating near that category must handle product information, seller claims, consumer education, and legal boundaries carefully. The fact that a marketplace or token exists does not resolve those issues.

Our ongoing disclosure commitment

We are publishing this notice so readers can evaluate our coverage with the financial interest in view. We will update this page if the position is materially increased, reduced, sold, or if Peptides Agora enters a formal commercial arrangement with PeptideSwap.

Readers should make their own decisions, seek independent professional advice where appropriate, and never treat editorial coverage as a substitute for financial, legal, or medical guidance.

[^1]: PeptideSwap official website, accessed October 26, 2026. PeptideSwap describes a marketplace project and learning lab, states that the $PEPS presale is open, and labels its token allocation as a working proposal.